Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

This study is testing an immunotherapy drug called tislelizumab as a first-line treatment for elderly patients with advanced esophageal squamous cell carcinoma who are too frail or medically unfit to receive standard chemotherapy. The goal is to offer an effective alternative to those who cannot tolerate traditional treatment. **You may be eligible if...** - You are 70 or older with confirmed esophageal squamous cell cancer that is advanced or has spread - You have not received any prior treatment (no immunotherapy, chemotherapy, or radiation) for this cancer in the first-line setting - Your oncologist and a geriatrics specialist have determined you are not suitable for platinum-based chemotherapy - You have at least one measurable or assessable tumor - Your overall health is rated as adequate (WHO performance status 0–2) - You are expected to live more than 3 months - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have already received treatment for this stage of cancer - You are fit enough for standard platinum-based chemotherapy - You have active autoimmune disease or are taking systemic steroids - You have untreated brain metastases - Your blood counts or organ function do not meet required levels Talk to your doctor to see if this trial is right for you.